AEON Biopharma
Yahoo Finance • 25 days ago
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use... Full story
Yahoo Finance • 30 days ago
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls
Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as c... Full story
Yahoo Finance • 3 months ago
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Key Points Dauntless Investment Group bought 116,863 shares of Innoviva in an estimated trade of $2.52 million last quarter. The quarter-end position value rose by $2.74 million, reflecting both trading and price movements. The post-trade... Full story
Yahoo Finance • 4 months ago
AEON Biopharma Sets Annual Shareholder Meeting
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP... Full story
Yahoo Finance • 5 months ago
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to... Full story
Yahoo Finance • 5 months ago
AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards
IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to... Full story
Yahoo Finance • 5 months ago
AEON Posts Net Loss In FY25; Plans To Request BPD Type 2b Meeting For ABP-450 In 2026; Stock Down
(RTTNews) - AEON Biopharma, Inc. (AEON), a biopharmaceutical company, announced financial results for the full year 2025, reflecting a net loss compared to a profit in the prior year. In addition, the firm provided a business update. Foll... Full story
Yahoo Finance • 5 months ago
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program
– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a c... Full story
Yahoo Finance • 9 months ago
AEON Biopharma GAAP EPS of -$0.39
* AEON Biopharma press release [https://seekingalpha.com/pr/20308149-aeon-biopharma-reports-third-quarter-2025-results-including-positive-abpminus-450] (AEON [https://seekingalpha.com/symbol/AEON]): Q3 GAAP EPS of -$0.39. * Reported a... Full story
Yahoo Finance • 9 months ago
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON’s analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional char... Full story
Yahoo Finance • 9 months ago
AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
- Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing with potential for over $7 million of additional capital via cash-exercise warrants - - Daewoong has entered... Full story
Yahoo Finance • last year
AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update
– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q’25 – – Type 2a meeting with the FDA anticipated in 4Q’25– – Cash runway expected to support op... Full story
Yahoo Finance • last year
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therap... Full story
Yahoo Finance • last year
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple ther... Full story
Yahoo Finance • last year
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
– Initiated analytical studies in Q4 2024to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025– – Pursuing a 351(k) regulatory pathway for ABP-450, which offer... Full story
Yahoo Finance • last year
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today ann... Full story
Yahoo Finance • 2 years ago
AEON Biopharma, Inc. Announces Reverse Stock Split
IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today anno... Full story
Yahoo Finance • 2 years ago
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today anno... Full story